Medicare AdvantagePrior AuthMedium impact
Tafinlar (dabrafenib) (Revised)
Humana·Oncology, Pediatrics·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has revised its prior authorization policy for Tafinlar (dabrafenib), effective January 1, 2026. The policy establishes specific coverage criteria for six cancer indications including melanoma, lung cancer, thyroid cancer, and pediatric brain tumors, all requiring BRAF mutation testing and combination therapy with Mekinist in most cases.
Action Required
By January 1, 2026: Clinical staff must ensure all Tafinlar (dabrafenib) prescriptions for Medicare Advantage patients include documented BRAF V600 mutation testing results and meet specific indication criteria. Update prior authorization request templates to include required combination therapy documentation (typically with Mekinist). Verify patient diagnosis matches one of six approved indications: unresectable/metastatic melanoma, adjuvant melanoma, NSCLC, anaplastic thyroid cancer, metastatic solid tumors, or pediatric low-grade glioma.